ClinicalTrials.gg

Program

HS-10506

A development code. Also written as “HS-10506, Itraconazole”.

In Hansoh Pharmaceutical Group's pipeline, OX2R antagonist. Its studies are mostly in Sleep Initiation and Maintenance Disorders · Lymphoma, Follicular, led by Hansoh Pharmaceutical Group.

Furthest: phase 3, since Apr 23, 20266 company-led studies, 6 open or runningNext primary completion: Jun 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group66 open or runningphase 3since Apr 23, 2026Jun 26, 2023Jun 1, 2028phase 1 · NCT07844967
  • Named in Hansoh Pharmaceutical Group’s own pipeline as HS-10506 (OX2R antagonist), phase 3, as of Aug 26, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 26, 2023First study: phase 1 study in HealthyFirst studyNCT05953506 · 52 planned
  2. Feb 18, 2024Phase 2 study in Sleep Initiation and Maintenance DisordersNCT06279286 · 312 planned · China
  3. Mar 20, 2026Phase 1 study in Healthy ParticipantsNCT07535970 · 20 planned · China
  4. Apr 23, 2026Phase 3 study in Sleep Initiation and Maintenance DisordersPhase 3 reachedNCT07587385 · 732 planned
  5. Jun 8, 2026Phase 3 study in Sleep Initiation and Maintenance DisordersNCT07677384 · 600 planned
  6. Jul 8, 2026Phase 1 study in Lymphoma, FollicularNCT07844967 · 32 planned · China

Ahead

  1. Jun 1, 2028Primary completion: phase 1 study in Lymphoma, FollicularNCT07844967
  2. Jun 28, 2028Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersNCT07587385
  3. Jun 30, 2029Primary completion: phase 3 study in Sleep Initiation and Maintenance DisordersNCT07677384

TargetBeta

“OX2R antagonist”the company's pipeline, read by Claude · source

Other programs on HCRTR2

ProgramCompanyFurthest phaseStudies
daridorexantruleIdorsia Pharmaceuticalsphase 434
seltorexantruleJohnson & Johnsonphase 333

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07844967Lymphoma, Follicular · China1RecruitingJun 1, 202832
NCT07677384Sleep Initiation and Maintenance Disorders3Not yet recruitingJun 30, 2029600
NCT07587385Sleep Initiation and Maintenance Disorders3Not yet recruitingJun 28, 2028732
NCT07535970Healthy Participants · China1Not yet recruitingJul 30, 202620
NCT06279286Sleep Initiation and Maintenance Disorders · China2Not yet recruitingJan 2025312
NCT05953506Healthy1Not yet recruitingDec 24, 202352

How it is read

Names in the registry

  • “HS-10506”, 5 entries
  • “HS-10506, Itraconazole”, 1 entry

Codes read as this program: HS10506.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.